INTRODUCTION
Breast cancer is still the second leading cause of cancer-related deaths among women in the United States [1] . This is largely due to the high mortality rate in metastatic disease.
Cytokines and chemokines in the tumor microenvironment are known to promote breast cancer progression and metastasis [2] . Significantly, interleukin-4 (IL4), a Th2 cytokine, is upregulated in the microenvironment of breast carcinomas [3] , and the IL4 receptor (IL4R) is overexpressed by breast cancer cells themselves [4] . In the immune system, IL4 is produced predominantly by activated T cells, mast cells, basophils, and eosinophils, and is known to regulate the survival, proliferation, and differentiation of B and T lymphocytes through IL4R [5] . Therefore, it is plausible that upregulated epithelial IL4R could promote breast tumor growth.
The IL4/IL4R interaction has been shown to enhance the proliferation and survival of breast cancer cells in vitro [6, 7] , and the survival of other epithelial cancer cell types in vivo [4] . and the IL4RD chain [5] . Heterodimerization is necessary for receptor functionality [8] . Nonlymphoid cells including breast cancer cells, express the type II IL4R, composed of the IL4R and IL13 receptor alpha 1 (IL13R 1) chains. Interleukin-13 (IL13) is the only other cytokine known to bind and activate type II IL4R's. However, IL4 binds with higher affinity and is the prototypical ligand for the IL4R [2] . In lymphoid cells, the IL4/type I IL4R interaction can result in the activation of two primary pathways: 1) insulin receptor substrate protein (IRS)/PI3K/Akt pathway; and 2) the JAK/signal transducer and activator of transcription factor (Stat6) pathway [5] . Activated Akt [9] and Stat6 [5, 10, 11] are known regulators of proliferation and survival. However, IL4RD
signaling from the type II IL4R may differ from the type I receptor. Demonstrative of this concept, the activation of Akt in response to IL4 appears to be context and cell type dependent [5, 12] , and IL4 has also been shown to activate Erk in several non-hematopoietic cell types [5] .
Here, we investigate whether IL4RD, a key component of the IL4R, can promote the metastatic colonization and outgrowth of mammary tumor cells, and explore mechanisms of IL4/IL4R-induced colonization ability in vitro.
MATERIALS AND METHODS

Cell Lines and Culture
The 4T1 cell line was acquired from Dr. Albert Reynolds at Vanderbilt University. PyVT-R221a cells were isolated from a polyoma middle T oncoprotein (PyMT) tumor as previously described [13] . The R221a line was authenticated by expression of the polyoma antigen, and the morphology and growth rates of both cell lines were consistently monitored. Cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) containing 10% fetal bovine serum (FBS, Atlanta Biologicals) at 37qC with 5% CO2. Mission lentiviral small hairpin RNA (shRNA) particles (Sigma) targeting two different regions of murine IL4RD (NM_010557) along with control non-target particles were used to infect 4T1 cells. Control non-target and specific murine IL4Ra-targeted shRNA lentiviral particles (Santa Cruz Biotechnologies) were used to infect R221a cells. Post-infection, shRNA-expressing cells were selected with puromycin 
Reagents and Antibodies
Murine IL4 was purchased from BD Biosciences. The small molecule inhibitors, U1026 (EMD Millipore), Ly294002, and rapamycin (both Sigma) were dissolved in dimethylsulfoxide (DMSO, Sigma) and diluted with culture medium to the appropriate concentration for western blots and clonogenic assays. The following antibodies were used to probe western blots: murine IL4RD, 
Commercial Arrays
A human tissue array containing 16 stage-IIIa/IIIb and 34 stage-IIa/IIb primary breast carcinomas from patients with lymph node metastases, cat#BR10010a, was purchased from US Biomax. The array was probed with antibodies for human IL4RD (Santa Cruz Biotechnologies) and pStat6 [pY641] (Sigma). Samples were scored categorically as positive or negative for IL4RD and pStat6. Conditioned media (serum free) from R221a or 4T1 combined sh-control or IL4RD KD clones was added to an antibody array to detect sixty-two murine secreted factors (RayBiotech Inc. #AAM-CYT-3-4) per manufacturer's instructions. Protein expression was quantified by densitometry in ImageJ£ relative to positive controls. 
Analysis of Murine Tumor Models
RESULTS
IL4RD
D expression and activation in human breast cancer and murine mammary cancer models To examine the relative abundance and activation of IL4RD in human breast cancers, we first immunostained a human tissue array consisting of 50 primary node-positive breast cancer samples for IL4RD and downstream phosphorylation of STAT6 (pSTAT6). A total of 82% of the samples were IL4RD positive, and 42% were positive for both IL4RD and pSTAT6 (Fig. 1A) .
The majority of carcinomas were classifiable by HER2 status (38 HER2 positive and 12 HER2 negative, of which 5 were triple negative). However, sample numbers were too low to make statistically significant correlations between subtype and IL4RD or pSTAT6 positivity.
Mammary tumors from the polyoma middle T oncogene transgenic mouse, and tumors resulting from orthotopic injection of R221a and 4T1 murine mammary cancer cells, were also positive for IL4RD and pStat6 ( Fig 1B) . Thus, human breast cancers and our murine models both show IL4 receptor expression and activation.
IL4RD promotes the growth of murine mammary tumor metastases in the lung and liver
Since the IL4/IL4R interaction is species-specific, only murine mammary tumor cell lines could be used to study functional roles of IL4 receptor signaling in mouse models. The 4T1 line was derived from a spontaneous mammary cancer in a BALB/c mouse [14] . The R221A line came from a mammary tumor in an MMTV-PyVT transgenic mouse on the FVB/N background [13] . Using commercially available lentiviral particles carrying short-hairpin RNA, we generated two clones representing different knockdown sequences for the 4T1 line. A separate mix of IL4RD-targeted shRNA sequences was used to make two different clones of R221A cells. were also stained with H&E, and used to calculate tumor burden. In both the R221a and 4T1 cell lines, reduced IL4RD expression resulted in a significant decrease in metastatic lung and liver tumor burden (Fig. 3A, 3B ).
We previously determined that neither R221a nor 4T1 cells produce detectable levels of (Fig. 3C ) and the lung tumor burden (Fig. 3D ) at endpoint were significantly decreased in IL4 KO mice compared to WT mice receiving sh-control cells. These results suggest that the IL4/IL4RD interaction is a strong promoter of lung metastatic tumor growth in vivo.
IL4RD D-associated survival and proliferation contribute to metastatic colonization and outgrowth
The metastatic seeding and outgrowth ability of R221a and 4T1 clones was estimated by quantifying tumor number and area, respectively, from the H&E-stained lung and liver sections (Fig. S1B, S1C ). The ability of R221a IL4RD knockdown clones to seed tumors was significantly reduced in both the lung (Fig. 4A) and liver (Fig. 4B ) compared to sh-control clones.
While the same was true for 4T1 IL4RD KD clones compared to sh-controls in the lung (Fig.   4A ), the decrease in seeding ability in the liver was not significant (Fig. 4B) . However, in both cell lines reduced IL4RD expression resulted in a significant decrease in lung (Fig. 4C ) and liver tumor outgrowth (Fig. 4D ).
In addition to quantifying tumor number and size, lung and liver metastases were stained for cleaved caspase-3 (apoptosis marker) and Ki67 (proliferation marker) to further examine the role of IL4RD in promoting the survival and outgrowth of metastatic tumors (Fig. S2) .
Differences in cleaved caspase-3 in the lungs of mice receiving either R221a or 4T1 IL4RD KD cells by tail vein injection were not statistically significant (Fig. 4E) . In R221a tumors this was likely due to the lack of assessable staining within very small KD tumors. Quantification of cleaved caspase-3 staining in liver metastases revealed a significant increase in apoptosis in IL4RD KD tumors of R221a, but not 4T1 recipient mice compared to sh-control (Fig. 4F) 
staining results were more consistent in that mice receiving either R221a or 4T1 IL4RD KD cells exhibited a significant reduction in proliferation in both lung (Fig. 4G ) and liver metastases (Fig.   4H ). These data suggest that IL4RD promotes the growth of murine mammary cancer cells at metastatic tumor sites through enhanced survival and colonization ability and increased proliferation for outgrowth. (Fig. 5D ). Macrophage inflammatory protein-2 (MIP-2) was the only cytokine that increased greater than 2-fold in KD clones for both cell lines. Leptin receptor has no known direct role in immune cell recruitment, however this protein was also upregulated greater than 2-fold by both R221a and 4T1 KD clones. 
Changes in immune infiltration
Thus, while it is possible that increased MIP-2 production from IL4RD KD clones may lead to enhanced leukocyte recruitment, we were unable to identify robust patterns of cytokine production that differed between sh-control and IL4RD KD cells.
IL4-activated Akt, Erk and mTor mediate colonization ability of mammary cancer cells
Our in vivo data establishes that the IL4 receptor mediates enhanced colonization of mammary cancer cells at metastatic sites, and that host IL4 promotes the growth of lung tumor metastases. Therefore, we used exogenous IL4 to elucidate signaling pathways that control Consistent with IRS1 inactivation and degradation [15, 16] , IRS1 [ser612] was also phosphorylated in response to IL4 in both cell lines in a temporal manner, and total IRS1 levels initially increased then rapidly decreased in the 4T1 cell line.
We next confirmed the specificity of the IL4/IL4RD interaction in promoting colonization ability in vitro. R221a or 4T1 combined sh-control or IL4RD KD cells were plated at clonal density in the presence or absence of IL4 with an IL4 blocking decoy receptor (IL4RD-FC), or an immunoglobulin G (IgG) control. The ability of IL4RD-FC to neutralize IL4-induced Stat6 activation at the dose used in clonogenic assays was confirmed by western blot (Fig 6A) .
As expected, the significant increase in colonization ability in response to IL4 was blocked by the addition of IL4RD-FC in control clones, but neither IL4 nor IL4RD-FC had a significant effect on the colonization ability of IL4RD KD clones for either cell line (Fig. S6B) colonization ability. U1026 was used to inhibit the activity of Erk1/2 [17] , and LY294002, a known PI3K inhibitor, was used to inhibit Akt phosphorylation at both sites (thr308 and ser473) [18] . First, the effective dose of inhibitor that decreased colony formation by 50% (ED50) was determined for each cell line (data not shown). Prior to their use in clonogenic assays, selected drug doses were also confirmed to inhibit IL4-induced activation of pErk1/2 or pAkt [thr308/ser473], by western blot (Fig. 6B) . Suggesting that IL4-activated Erk1/2 promotes initial colonization, U1026 treatment in both cell lines blocked IL4-induced colony formation (Fig. 7A) .
Treatment with LY294002 also blocked IL4-induced colony formation in the 4T1 cell line, but not the R221a line (Fig. 7B) .
A potential complication with LY294002 is that it also inhibits mammalian target of rapamycin (mTor) at concentrations slightly higher than the 50% inhibitory concentration (IC50) of PI3K [19] . We therefore also tested the effect of rapamycin. In both cell lines, combined IL4 and rapamycin treatment significantly reduced colony formation compared to IL4 treatment alone (Fig. 7C) . We then discovered by western blot that rapamycin treatment resulted in strong inhibition of IL4-activated mTor ser2481, but not mTor ser2448, indicating that activated mTorc2 rather than mTorc1 may be important in regulating IL4-induced colony formation (Fig.   6B ).
To evaluate whether the signaling pathways identified in vitro were relevant in vivo, we immunostained for pAkt [ser473], pErk1/2, and pmTor [ser2481] in R221a and 4T1 sh-control and IL4RD KD lung metastases (Fig. S7) . The anti-pmTor [ser2481] antibody selectively labeled mitotic cells with high intensity and did not provide useful information. However, we were able to confirm a significant reduction in both pErk1/2 and pAkt [ser473] in IL4RD KD R221a and 4T1 lung metastases compared to sh-controls (Fig. 7D, E) . [20] . However, the majority of these studies utilized in vitro assays and subcutaneous xenograft models in nude mice. Here, we have established the relevance of IL4RD expression in human breast cancer and in two syngeneic murine models of breast cancer (Fig. 1) . Using murine models we have defined a novel role of epithelial IL4RD in promoting metastatic mammary tumor growth.
Using R221a and 4T1 IL4RD knockdown (KD) clones and wild-type mice in
experimental metastasis assays we demonstrated that reduced IL4RD expression results in significantly attenuated metastatic tumor burden in both the lung and the liver (Fig. 3) . This reduced burden was also seen in the lungs of IL4 -/-mice injected with control cells, indicating that reducing either the ligand or receptor can attenuate metastatic growth (Fig 3C, D) . Notably,
IL4
-/-mice injected with IL4RD KD cells showed a greater reduction in tumor burden than either IL4 -/-or IL4RD KD alone. This could be partially explained by incomplete KD of IL4RD, but may also reflect a role for the other type II IL4R ligand, IL13 in vivo. Decreased metastatic ability of IL4RD knockdown clones was attributed to 1) reduced tumor cell survival as determined by seeding ability (number of tumors) and an increase in apoptosis by cleaved caspase-3 positivity, and 2) a reduction in proliferation determined by tumor outgrowth ability (tumor size) and a decrease in Ki67 positivity (Fig. 4) . In some cases, differences in these parameters were not significant at endpoint, which may be attributable to changes that occurred 
earlier in tumor development. Additionally, there are large differences in the growth rates of the cell lines. The aggressive and highly metastatic 4T1 line is typically used to establish models representative of clinical stage four breast cancer whereas R221a cells rarely metastasize spontaneously, and may represent less aggressive breast cancers. This growth disparity is most evident in the H&E stained images of the 4T1 livers (Fig. S1D) , where large tumors were difficult to delineate from each other.
In addition to proliferation and survival, we examined whether immune infiltrates contributed to the reduction in KD tumor size. We saw increases in almost all leukocyte populations examined in both R221a and 4T1 KD metastases (R221a: Fig. 4, 4T1 Fig. S5 ). Thus our results overall suggest that more efficient clearance of KD tumor cells could contribute to the reduction in tumor size visualized at endpoint compared to sh-control tumors.
It is feasible that enhanced production of pro-inflammatory cytokines from IL4RD KD cells could recruit immune cells to these tumors. However, out of sixty-two secreted proinflammatory factors examined by cytokine array, only MIP-2 was increased greater than 2-fold by IL4RD KD cells in comparison to sh-controls for both cell lines (Fig. 5D ). MIP-2 secreted from epithelial cells enhances neutrophil and lymphocyte recruitment [21] . Leptin/leptin receptor signaling reportedly induces MIP-2 production in pre-neoplastic colon cells [22] .
Therefore, the increased expression of leptin (> 1.5-fold) and its receptor (> 2-fold) within IL4RD KD tumors could also facilitate neutrophil and lymphocyte recruitment. Still, strong patterns of cytokine production from IL4RD KD cells were lacking, indicating that other mechanisms may contribute to IL4RD-induced survival and proliferation ability at metastatic sites. 
The Jak/Stat6 pathway is activated by the IL4/IL4RD interaction in lymphoid cells [5] , and in several epithelial cancer cell types including breast cancer (Fig. 1, [7] ). We were able to confirm activation of IL4R in vitro via phosphorylation of downstream Stat6 in response to IL4 (Fig. 6A) . Stat6 has been shown to regulate pro-metastatic processes including migration and invasion [23] and enhanced survival and proliferation in vitro [4, 7, 21] , although one study showed that Stat6 activation decreased between ductal carcinomas in situ and invasive breast ductal carcinomas [24] . That study did not examine IL4RD expression, or other IL4/IL4RD-activated pathways including PI3K/Akt and MAPK/Erk that may be important for the promotion of metastatic phenotypes in vivo.
Using the Mek inhibitor, U1026, we determined that IL4-activated Erk1/2 promotes the colonization ability of mammary cancer cells in vitro (Fig. 7A) . The PI3K/Akt pathway inhibitor, LY294002, blocked IL4-activated Akt in both cell lines, but only abrogated colony formation in the R221a line (Fig. 7B) . The R221a cells express the middle T oncoprotein, a strong driver of constitutive PI3K/Akt and Src kinase activity, which would be unaffected by LY294002 treatment [25] . These results confirm previous reports that activation of Akt in response to IL4 is cell type/context dependent [5, 12] .
We next examined whether IL4-activated mTor could promote IL4-induced colony formation for two reasons: 1) Akt was phosphorylated at ser473 in both cell lines in response to IL4 (Fig. 6A) ; and 2) LY294002 is known to fit in the active catalytic domain of mTor and inhibit its activity at slightly higher concentrations than the IC50 for PI3K inhibition [19] .
Rapamycin, a potent mTorc1 inhibitor, has also been shown to inhibit ser2481 phosphorylation and mTorc2 [26] . Use of this compound in vitro demonstrated that IL4-activated mTorc2 R221a and 4T1 cell lines (Fig. 6B, Fig. 7C ). Our findings are consistent with a previous report demonstrating that mTorc2 but not mTORC1 mediates the survival of breast cancer cells [27] .
Insulin receptor proteins (IRS) proteins mediate the activation of several signaling pathways in response to IL4 [27, 28] . IRS1 expression in breast cancers is often decreased in high-grade invasive tumors compared to well-differentiated tumors [24, 31, 32] . Also, IRS1 in murine lung metastases is inactivated by serine phosphorylation, and loss of IRS1 expression in murine mammary cancer cells led to increased lung metastases [32] . Serine phosphorylation of IRS1 for inactivation and/or proteasomal degradation is known to be mediated by several kinases including mTor, Akt, and Mapk [33] , three effector proteins activated in response to IL4 (Fig. 6 ).
In R221a and 4T1 cells, ser612 is phosphorylated in a time dependent manner after IL4 (Fig. 6A ).
This may explain the eventual decrease of total IRS1 protein levels in 4T1 cells (Fig. 6A) . These results indicate that IL4 signaling may induce the inactivation and proteasomal degradation of IRS1, thus removing a potential metastasis-suppressor.
In conclusion, we have demonstrated for the first time that the IL4/IL4RD interaction promotes mammary metastatic tumor growth, and that loss of IL4RD in mammary cancer cells results in reduced survival and proliferation and decreased colonization and outgrowth at metastatic sites. It is known that the Mapk/Erk, and PI3K/Akt/mTor signaling axes are potent drivers of breast cancer growth [26, 27] . We have shown that Erk, Akt, and mTor are downstream effectors of the IL4RD-associated pro-metastatic colonization phenotype. termed "superkines," are capable of specifically targeting the type II IL4 receptor, and are being tested for improving cytokine therapy selectivity [36] . We raise the possibility of using such agents to target the type II IL4 receptor on breast cancer cells as a novel means to thwart metastatic tumor growth. 
